The FDA will investigate the risk of severe hypocalcemia that results in hospitalization and death with Amgen’s osteoporosis drug, Prolia (denosumab).
Read the full post on Becker's Hospital Review - Healthcare News
FDA probes severe hypocalcemia risk with Amgen’s osteoporosis drug
